Skip to main content
. 2016 Feb 25;1(2):e85817. doi: 10.1172/jci.insight.85817

Figure 1. Heme oxygenase-1 overexpression prevents doxorubicin-induced cardiac toxicity.

Figure 1

(A) Schematic of the treatment protocol utilized in this study. Mice were administered three 6.0 mg/kg doses of intravenous doxorubicin (DOX) every third day for a week and euthanized for tissue collection. To assess cardiac function, mice underwent serial echocardiography the day before DOX administration and up to 14 days after treatment. (B) Heme oxygenase-1 (HO-1) overexpression in humanized HO-1 overexpressing (HBAC) mice was confirmed by Western blot on tissue lysates generated from the left ventricle (LV). GAPDH was used as a loading control. (C) Ejection fraction (EF), (D) end diastolic diameter (EDD), and (E) end systolic diameter (ESD) were measured by serial echocardiography. Black bars depict data from WT mice, white bars depict data from HBAC mice. Data are presented as mean ± SEM. *P < 0.05, 2-tailed paired t test was used to determine statistically significant changes after DOX treatment, relative to baseline values; n = 5–8 per group.